Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Shree Ganesh Biotech (India) Ltd, at its meeting on 8 November 2025, approved the unaudited financial results for the quarter and half year ended 30 September 2025, which were subjected to a limited review by statutory auditors BIPIN & Co. (clean, unqualified review report). Revenue from operations fell sharply to Rs. 76.74 lakhs in Q2 FY26 from Rs. 198.40 lakhs in Q2 FY25, a decline of about 61% year-on-year, while H1 FY26 revenue dropped to Rs. 215.10 lakhs from Rs. 554.01 lakhs in H1 FY25. Net profit for the quarter fell to just Rs. 1.41 lakhs (EPS Rs. 0.00) versus Rs. 32.34 lakhs a year ago, with H1 PAT at Rs. 34.11 lakhs vs Rs. 56.12 lakhs. Operating cash flow turned sharply negative at Rs. -68.18 lakhs in H1 FY26 against a positive Rs. 665.98 lakhs last year. The balance sheet shows new short-term borrowings of Rs. 143.18 lakhs, investments of Rs. 915 lakhs, and long-term loans of Rs. 5,163.39 lakhs.
Sharply lower revenue, near-zero quarterly profit, and a swing to negative operating cash flow point to weakening business activity and are negative for the stock. The auditor's clean review report and absence of any restatement or exceptional items provide some comfort, but shareholders should watch for improvement in topline in coming quarters.